Welcome to our Evotec Blog.

Hope you will find our articles and resources relevant for your projects and interests.

Our experts are available for any additional information and to assist with your project challenges!

Just contact us.

 

 

2018

Evotec partner Haplogen enters into collaboration with Bayer
Nerina Coppini, 14 August 2018

Focus on pulmonary diseases with high unmet medical need Integrated Haplogen-Bayer collaboration builds upon pulmonary portfolio created by Evotec and Haplogen Evotec will participate in undisclosed upfront as well as potential milestone and royalty-based payments from Bayer to Haplogen

Evotec receives milestone payment for start of Phase II trial in its multi-target alliance with Bayer
Nerina Coppini, 19 July 2018

Hamburg, Germany, 19 July 2018: Hamburg, Germany, 19 July 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its multi-target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II clinical development for the treatment of chronic cough, resulting...

Evotec and Bayer Advance Third Endometriosis Programme into Phase I Clinical Development
Nerina Coppini, 18 April 2018

Hamburg, Germany, 18 April 2018:Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating reproductive condition that affects approximately 176 million women...

 

 

Contact us

Evotec

Business Development

T +44.(0)1235.86 15 61 T +1.732 329 2355 x3308